J
Janet E. Price
Researcher at University of Texas MD Anderson Cancer Center
Publications - 122
Citations - 8550
Janet E. Price is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Metastasis & Cancer. The author has an hindex of 48, co-authored 122 publications receiving 8221 citations. Previous affiliations of Janet E. Price include University of Texas at Austin & University of Texas Health Science Center at Houston.
Papers
More filters
Proceedings ArticleDOI
Abstract 3208: Overcoming cancer therapeutic resistance by targeting dysregulated glucose metabolism
Yuhua Zhao,Ming Zhou,Susan P. LeDoux,Glenn L. Wilson,Dihua Yu,Janet E. Price,Øystein Fodstad,Ming Tan +7 more
TL;DR: It is found that combining trastuzumab or Taxol with glycolysis inhibition synergistically inhibited both drug-sensitive and -resistant breast cancers in vitro and in vivo, due to more efficient inhibition of gly colysis.
Book ChapterDOI
Einfluß der Leberregeneration auf das biologische Verhalten menschlicher Tumormetastasen in der thymuslosen Nacktmaus
TL;DR: The Regenerationsfahigkeit der Leber is ein Prozes, der durch unbekannte Faktoren im Pfortaderblut ausgelost wird, in eine massive, kurz anhaltende Proliferationswelle mundet und einer prazisen zeitlichen Steuerung unterliegt as mentioned in this paper.
Proceedings ArticleDOI
The Anti-Tumor Effect of Motesanib in Pre-Clinical Models of Human Basal-Like Breast Cancer.
Janet E. Price,Ricardo H. Alvarez,C. Xu,Anthony Polverino,Robert Radinsky,Angela Coxon,Douglas Saffran +6 more
TL;DR: This study determined the effects of motesanib on the growth of human basal-like breast cancer cell lines in immunodeficient mice, alone and in combination with paclitaxel and produced dose-dependent inhibition of growth of BT-549, GILM2 and HCC1187 tumors.
Patent
SKI 606 as src kinase inhibitor for treating osteolytic lesions
TL;DR: In this article, methods and compositions for treating bone-resorbing diseases or bone resorption related to a pathologic condition generally, including, but not limited to osteoporosis, arthritis, rheumatoid arthritis, cancer metastases to the bone, bone cancer, hypercalcemia, osteolytic lesions with orthopedic implants, Paget's disease, and bone loss associated with hyperparathyroidism.